Kim JH, et al. - Researchers evaluated the long-term impact of tyrosine kinase inhibitors (TKIs), including imatinib, and surgical intervention, on advanced gastrointestinal stromal tumor (GIST) by analyzing 379 patients who had metastatic or recurrent GIST and started 400 mg/d imatinib at the Asan Medical Center in periods 1 and 2 (2001-2007 [33.2%] and 2008-2014 [66.8%], respectively). Favorable progression-free survival and overall survival were noted in correlation with young age, smaller tumor size at the initiation of imatinib, KIT exon 11 mutation, surgical intervention, and period 2. Findings revealed better prognosis in patients with advanced GIST with the optimal use of imatinib, along with active surgical intervention and more common use of subsequent TKIs in period 2.